Heron Therapeutics Inc (HRTX) Given Average Recommendation of “Buy” by Brokerages

Shares of Heron Therapeutics Inc (NASDAQ:HRTX) have been assigned an average rating of “Buy” from the thirteen analysts that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $31.13.

HRTX has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Monday, September 25th. Mizuho initiated coverage on shares of Heron Therapeutics in a research report on Tuesday, September 26th. They issued a “buy” rating and a $28.00 price objective for the company. Northland Securities initiated coverage on shares of Heron Therapeutics in a research report on Wednesday, September 27th. They issued an “outperform” rating and a $40.00 price objective for the company. Noble Financial reiterated a “buy” rating and issued a $24.00 price objective on shares of Heron Therapeutics in a research report on Friday, October 6th. Finally, Oppenheimer initiated coverage on shares of Heron Therapeutics in a research report on Monday, October 30th. They issued a “buy” rating and a $27.00 price objective for the company.

In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the company’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total value of $151,680.00. Following the completion of the transaction, the vice president now owns 7,584 shares in the company, valued at $151,680. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 19.93% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Legal & General Group Plc raised its position in shares of Heron Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 2,383 shares during the last quarter. Quantbot Technologies LP raised its position in shares of Heron Therapeutics by 2,619.6% during the 2nd quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock worth $172,000 after purchasing an additional 12,024 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Heron Therapeutics during the 3rd quarter worth about $206,000. Jane Street Group LLC acquired a new position in shares of Heron Therapeutics during the 3rd quarter worth about $223,000. Finally, HighTower Advisors LLC raised its position in shares of Heron Therapeutics by 11.4% during the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 1,700 shares during the last quarter. Institutional investors and hedge funds own 98.21% of the company’s stock.

Heron Therapeutics (NASDAQ HRTX) traded up $0.30 during trading hours on Friday, reaching $23.20. 915,369 shares of the company’s stock traded hands, compared to its average volume of 1,120,538. Heron Therapeutics has a one year low of $12.25 and a one year high of $23.35. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12. The stock has a market capitalization of $1,260.00, a price-to-earnings ratio of -6.12 and a beta of 2.12.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The company had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. research analysts predict that Heron Therapeutics will post -3.38 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/19/heron-therapeutics-inc-hrtx-given-average-recommendation-of-buy-by-brokerages.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply